Cargando…
Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review
Upadacitinib is a selective and reversible Janus kinase (JAK) inhibitor recently approved by the European Medicine Agency and the Food and Drug Administration for the treatment of rheumatoid arthritis (RA) at a dose of 15 mg/day. We present the chemical structure and mechanism of action of upadaciti...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002765/ https://www.ncbi.nlm.nih.gov/pubmed/36902522 http://dx.doi.org/10.3390/jcm12051734 |